Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss

ARROWHEAD PHARMACEUTICALS, INC.

2022-Q2 EPS reported -$0.18 revenue$179,244,000

Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.
Initiated PALISADE Phase 3 study of ARO-APOC3 in familial chylomicronemia syndrome; completed enrollment of 204 patients in Phase 2b ARCHES-2 for ARO-ANG3.
Formed Visirna Therapeutics joint venture with Vivo Capital to expand into Greater China.
Broke ground on new manufacturing facility; awarded up to $18.5M in tax incentives from Wisconsin and Verona.
Total cash and investments of $603.5M as of March 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.